In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OSI Buys Eyetech, Market Rubs Eyes

Executive Summary

Not the most obvious of biotech-biotech combinations. OSI thinks it can make money from Eyetech's lone product pegaptanib (Macugen), a breakthrough new treatment for age-related macular degeneration. The market has reacted poorly to the deal, worried that Macugen will be made obsolete by Genentech's Lucentis, due to be launched in late 2006.

You may also be interested in...



Ophthotech Corp.

Ophthotech is creating drugs to be used in combination with anti-VEGF therapies for wet AMD. It is developing inhibitors of platelet-derived growth factor and the a5b1 integrin, as well as an anti-C5 receptor aptamer that could eventually be a therapy for both wet and dry forms of age-related macular degeneration.

Archemix Reduces Aperture to Pursue Orphan Diseases

Archemix has consolidated IP in the aptamer space and enjoyed success in partnering its technology. But public markets have frozen the company out and it is now focusing on orphan hematologic diseases. The move should help the company conserve cash while creating earlier out-licensing opportunities as Archemix transitions into later-stage development.

Archemix Reduces Aperture to Pursue Orphan Diseases

Archemix has consolidated IP in the aptamer space and enjoyed success in partnering its technology. But public markets have frozen the company out and it is now focusing on orphan hematologic diseases. The move should help the company conserve cash while creating earlier out-licensing opportunities as Archemix transitions into later-stage development.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV002628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel